Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15449326 | 0.91 | BACE1 (0.50) | BACE1APP | |
| SCHEMBL30393 | 0.91 | BACE1 (0.50) | BACE1APP | |
| SCHEMBL1465236 | 0.91 | BACE1 (0.50) | BACE1APP | |
| SCHEMBL1466510 | 0.91 | BACE1 (0.50) | BACE1APP | |
| SCHEMBL10250018 | 0.85 | BACE1 (0.39) | BACE1APP | |
| SCHEMBL19514264 | 0.82 | BACE1 (0.40) | BACE1 | |
| SCHEMBL19514344 | 0.82 | BACE1 (0.40) | BACE1 | |
| SCHEMBL1464631 | 0.82 | BACE1 (0.47) | BACE1APP | |
| SCHEMBL16621494 | 0.82 | BACE1 (0.47) | BACE1APP | |
| SCHEMBL1465376 | 0.82 | BACE1 (0.47) | BACE1APP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130210837-A1 | Compounds and Their Use as BACE Inhibitors | ASTRAZENECA INTELLECTUAL PROPERTY | 2013-08-15 | — | — | US | disclosed |
| US-8415483-B2 | Compounds and their use as BACE inhibitors | ASTRAZENECA AB (SE) | 2013-04-09 | — | — | US | disclosed |
| US-20120165347-A1 | Compounds and their use as BACE Inhibitors | ASTRAZENECA AB (SE) | 2012-06-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120165347-A1 | Compounds and their use as BACE Inhibitors | BACE1, BACE2, APP | BACE1 1/4885APP 3/4885 |
| US-20130210837-A1 | Compounds and Their Use as BACE Inhibitors | BACE1, BACE2, APP | BACE1 1/4885APP 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.